News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ariad Pharmaceuticals, Inc. (ARIA) Reports First Quarter 2014 Financial Results And Development Progress



5/7/2014 8:20:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the first quarter of 2014, including revenue from sales of Iclusig® (ponatinib) and licensing agreements. The Company also provided an update on corporate developments.

“As we reintroduce Iclusig into the U.S. market and continue with the European launch this year, our key priorities are to rebuild confidence in Iclusig and to improve the benefit/risk profile of the drug,” said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES